Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis by Bansal, Mukesh et al.
RESEARCH ARTICLE
Elucidating synergistic dependencies in lung
adenocarcinoma by proteome-wide signaling-
network analysis
Mukesh Bansal1,2☯*, Jing He3,4,5☯, Michael Peyton6☯, Manjunath KustagiID3,
Archana Iyer3, Michael Comb7, Michael White6, John D. Minna8,
Andrea CalifanoID3,4,5,9,10,11*
1 Psychogenics Inc., Paramus, New Jersey, United States of America, 2 Department of Neuroscience, Icahn
School of Medicine at Mount Sinai, New York, NY, United States of America, 3 Department of Systems
Biology, Columbia University, New York, NY, United States of America, 4 Center for Computational Biology
and Bioinformatics (C2B2), Columbia University, New York, NY, United States of America, 5 Department of
Biomedical Informatics (DBMI), Columbia University, New York, NY, United States of America, 6 Department
of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, United States of America,
7 Cell Signaling Technology, 3 Trask Lane, Danvers, MA, United States of America, 8 Hamon Center for
Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Pharmacology,
and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of
America, 9 Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY,
United States of America, 10 Institute for Cancer Genetics, Columbia University, New York, NY, United
States of America, 11 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY,
United States of America
☯ These authors contributed equally to this work.
* mukesh.bansal@psychogenics.com(MB); ac2248@cumc.columbia.edu(AC)
Abstract
To understand drug combination effect, it is necessary to decipher the interactions between
drug targets—many of which are signaling molecules. Previously, such signaling pathway
models are largely based on the compilation of literature data from heterogeneous cellular
contexts. Indeed, de novo reconstruction of signaling interactions from large-scale molecu-
lar profiling is still lagging, compared to similar efforts in transcriptional and protein-protein
interaction networks. To address this challenge, we introduce a novel algorithm for the sys-
tematic inference of protein kinase pathways, and applied it to published mass spectrome-
try-based phosphotyrosine profile data from 250 lung adenocarcinoma (LUAD) samples.
The resulting network includes 43 TKs and 415 inferred, LUAD-specific substrates, which
were validated at >60% accuracy by SILAC assays, including “novel’ substrates of the
EGFR and c-MET TKs, which play a critical oncogenic role in lung cancer. This systematic,
data-driven model supported drug response prediction on an individual sample basis,
including accurate prediction and validation of synergistic EGFR and c-MET inhibitor activity
in cells lacking mutations in either gene, thus contributing to current precision oncology
efforts.
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Introduction
Lung adenocarcinoma (LUAD) is a leading cause of cancer related deaths in United States,
representing 40% of 225,500 new lung cancer cases every year, and has a 5-year survival rate of
only 16% [1]. Excluding immunotherapeutic agents, which have recently shown significant
success in a relatively small subset of patients [2], the most effective targeted therapies for this
diseases were designed to inhibit tyrosine kinase proteins harboring genetic alterations that
induce aberrant activation of downstream pathways [3–7]. Among these, the most frequent
actionable alterations include EGFR mutations and EML4-ALK fusion events, in ~15% and
~3–7% of LUAD patients, respectively [8, 9]. Yet, while targeted therapy is initially effective in
a significant fraction of tumors harboring these genetic alterations, the vast majority of treated
patients will either fail to respond or will develop resistance to mono-therapy [10, 11]. In addi-
tion, most patients lack actionable alterations altogether. This suggests that novel approaches
are critically needed.
A possible alternative to minimize emergence of resistance is combination therapy, a strat-
egy that has been shown to be effective in many metastatic tumors, such as breast cancer and
acute myeloid leukemia [12–14]. However, systematic identification of effective drug combi-
nations on a genetic alteration basis is difficult, because the number of patients presenting
multiple actionable events is extremely low. As a result, combination therapy is generally
hypothesized and tested on an empirical basis or based on elucidation of complex mechanisms
of tumor cell adaptation. In addition, accurate prediction of response to available mono-ther-
apy–including to EGFR inhibitors–in patients lacking any genetic alteration represents an
equally relevant challenge, especially since a small fraction of EGFRWT patients have been
shown to respond to Afatinib [15], even though a predictive biomarker is not available. To
address these limitations, we and other have proposed that rational design of combination
therapy and the identification of critical targetable dependencies may require a more mecha-
nistic and tumor-context-specific understanding of the molecular interactions that underlie
their potential synergistic activities, starting with tyrosine kinases, which represent a critical
class of pharmacological targets in cancer [16]. Such approach requires methodologies for the
accurate and systematic elucidation of tumor-specific signaling transduction pathways.
Dissection of signal transduction networks represents a complex endeavor, requiring eluci-
dation of thousands of tissue-specific molecular interactions that mediate the post-transla-
tional modification of protein substrates. In vitro approaches generally fail to capture the
tissue-specific nature of these interactions, thus providing “average” signal transduction path-
ways that are both incomplete and inaccurate. In addition, experimental approaches that have
been successful in accelerating the analysis of molecular interactions in transcriptional regula-
tion and protein-protein interaction in stable-complexes, such as those based on co-expression
or yeast-2-hybrid assays, do not easily translate to elucidate signaling interactions. Similarly,
approaches based on the use of phospho-specific antibodies, while elegant and effective, are
limited to only a handful of proteins. Computationally, compared with the many algorithms
that have been developed for the reverse engineering of transcriptional and protein-complex
interactions [17, 18], only a handful of experimentally validated algorithms are available for
the dissection of signaling networks, none of which works at the proteome-wide level or is
tumor-context specific [17, 19, 20].
Recent availability of proteome-wide molecular profile data, characterizing the abundance
of phospho-tyrosine-enriched peptides by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS), suggests that additional methodologies may be developed to
extend approaches that have been successfully applied to the dissection of transcriptional net-
works from gene expression profiling. In this manuscript, we propose innovating the
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Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNe) [21] for the
reverse engineering of signal transduction networks from large-scale phosphoproteomic
profiles.
We applied pARACNe to the analysis of previously published, global tyrosine phosphopro-
teomic data from 245 lung adenocarcinoma (LUAD) samples, including 151 tumor samples,
46 cell lines, as well as 48 normal lung tissues [22]. The resulting network comprised 46 tyro-
sine kinases (TK) densely connected with 415 candidate substrates (including 377 proteins
lacking any TK activity), representing the first global tyrosine phosphoproteomics, tumor-con-
text-specific model for a TK signal transduction network, capturing both protein-specific and
phospho-site specific events. We validated substrate predictions for two “hubs”, whose activity
may play a key role in determining sensitivity to Erlotinib and Crizotinib, two FDA-approved
drugs for LUAD, including the EGFR and c-MET tyrosine kinases by independent SILAC
assays and database analysis, with >60% accuracy. Of particular note, the inferred TK-sub-
strate network provided unique information about tyrosine kinase auto-phosphorylation
events, either direct (cis) or via a second kinase (trans).
Analysis of the resulting TK-network–by extending the VIPER (Virtual Proteomics by
Enriched Regulon analysis) algorithm [23], an established method for the inference of Master
Regulator proteins–recapitulated established genetic determinants of LUAD and was effective
in predicting sensitivity to Erlotinib and Crizotinib combination therapy. Predicted sensitivi-
ties were validated in an independent set of LUAD cell lines, the majority of which harbored
no genetic alterations in the corresponding genes. Furthermore, predictions based on the anal-
ysis of the corresponding patient cohort were strongly supported by genomic information,
suggesting potential value in using these analyses for the identification of effective combina-
tion therapies in precision oncology.
Results
We started with construction of signaling network based on published global phosphoproteo-
mic data (Fig 1A, step 1). To do this, we introduce a novel algorithm for the systematic infer-
ence of protein kinase pathways based on the phosphotyrosine proteomics profile data from
250 lung adenocarcinoma (LUAD) samples. Then, based on this signaling network, we used
phospho-network based VIPER to identify candidate synergistic kinases for LUAD (Fig 1A,
step 2). Finally, we validated the synergistic drug combinations identified in step 2 using both
long-term and short-term drug treatment experiment (Fig 1A, step 3).
Overview of the pARACNe algorithm
Enzymatic activity of tyrosine kinase (TK) proteins–as assessed by the ability to phosphorylate
their downstream substrates–is effectively determined by their phosphorylated isoform abun-
dance (Fig 1B). Therefore, we reasoned that computational inference of TK-substrate interac-
tions (TK!S) could be effectively performed by measuring dependencies between their
respective phospho-states by mutual information analysis [24] over a large sample compen-
dium (Fig 1C, step 1). Unfortunately, due to signal transduction cascade complexity and path-
way cross-talk, such dependencies can manifest between protein pairs that are not involved in
direct TK!S interactions. The ARACNe algorithm–previously designed for the reverse engi-
neering of transcriptional networks–effectively addresses this problem by leveraging the Data
Processing Inequality [25]. This is a critical property of the mutual information that effectively
allows disambiguating between direct and indirect interactions by assessing whether informa-
tion transfer on any candidate direct interaction (e.g., TK1!S) is greater than transfer on
every other indirect path (e.g., TK1!TK2!S). ARACNe has been highly successful in the
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Fig 1. Framework for the reverse engineering of TK signaling networks from phosphoproteomic profiles. (A) Workflow
to identify pharmacological synergistic dependencies based on context-specific signaling network analysis. (B) Top panel
shows the schematic diagram of a TK!S interaction. The non-phosphorylated kinase is inactive in terms of
phosphorylating a substrate, while the active isoform successfully phosphorylates the substrate. Bottom panel shows
schematic diagram showing the correlation between TK phosphorylation and that of its potential substrates. The first two
rows in the heatmap show proteins representing candidate TK substrates (C) Illustration of the pARACNe framework
including 6 steps. Step-1 depicts peptides collection from primary lung cancer tissue and cell lines for whole
phosphrtyrosine proteomics quantification. Step-2 depicts inferences of TK!S interactions using Mutual Information by
Step-3 of the iterative quantile discretization methods and Step-4 Naïve-Bayes estimator. Step-5 and 6 depict network
pruning and bootstrapping to construct final network. (C) Framework of pARACNe from LC-MS/MS data normalization,
Iterative Quantile Discretization (IQD) process, Mutual Information (MI) calculation, Data Processing Inequality (DPI)
process, bootstrapping to network consolidation.
https://doi.org/10.1371/journal.pone.0208646.g001
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experimentally validated dissection of transcriptional networks via analysis of large gene
expression profile compendia. ARACNe-inferred targets of transcription factors were vali-
dated in multiple cellular contexts, with an accuracy of 70% to 80% [21, 26–29].
However, ARACNe relies on molecular profile data that is both continuous and non-sparse,
properties that are not always provided by quantitative proteomic data sets, which can be gen-
erated by a variety of methods. Those based on LC-MS/MS represent the most popular
approaches [30], but different implementations have specific performance profiles in terms of
analyte throughput, consistency of measurement of peptides across samples and linear
dynamic range [31]. Depending on the data acquisition method, one or both of these assump-
tions of ARACNe are violated in proteome-wide datasets generated by the most popular meth-
ods based on data-dependent acquisition. Particularly when employing quantification by
spectral counting, as is typically conducted for global protein-protein interaction studies [32,
33], phosphoproteomic data is both discrete (i.e., generally represented by spectral counts) and
very sparse, with a majority of peptides having zero spectral counts and presenting a signifi-
cantly skewed distribution for low-abundance peptides.
To address these limitations, we developed a phospho-proteomic specific algorithm, pARA-
CNe (phospho-ARACNe) (Fig 1C), specifically designed to measure phospho-state dependencies
between TKs and their candidate substrates from large-scale LC-MS/MS phosphoproteomic pro-
files. pARACNe thus extends the original ARACNe framework to allow systematic inference of
TK!S interactions. Specifically, to handle the highly discrete nature of the data, we replaced the
kernel-density and adaptive partitioning based mutual information estimators in the original algo-
rithm with a bin-count based method (Fig 1C, step 4), using gold standard data to select the most
effective number of bins [12] (see Methods). Furthermore, to deal with the skewed spectral count
distribution, we introduce an iterative quantile discretization method, where samples are binned
together, based on their spectral counts, to produce a distribution as close to uniform as possible
(Fig 1C, step 3, Methods).
pARACNe-inferred LUAD-specific TK-phosphorylation network
We used pARACNe to reconstruct a LUAD-specific TK-signaling network, by analyzing phos-
phopeptide profiles obtained from 245 LUAD samples from Guo et al. [34]. These data repre-
sent the abundance of peptides containing at least one phospho-tyrosine, as obtained by
phosphoproteomic analysis of 46 LUAD cell lines, 151 LUAD tumors, and 48 adjacent normal
samples. LC-MS/MS profiling produced spectral counts for 3,920 phospho-tyrosine containing
peptides mapping to ~2,600 different proteins. Based on these data, pARACNE identified
2,611 candidate phospho-peptide/phospho-peptide dependencies, which could be further
mapped to 2,064 unique TK!S interactions (S1 and S2 Tables). These represent interactions
between 46 unique TKs and their candidate substrates. These include 174 TK1!TK2 interac-
tions between two TKs (Fig 2A), representing a statistically significant bias toward TK-TK
interactions in the network (p = 10−62). This suggests that, within the complete TK signaling
network, TKs themselves may form a more densely inter-connected subnetwork than previ-
ously assessed, providing potentially valuable novel information about adaptive response,
pathway cross-talk, and auto-regulatory loops.
Such highly interconnected structure provides potential functional advantage compared to
less interconnected (i.e., “flat”) architectures, including the ability to provide more fine-grain
response to a highly heterogeneous variety of exogenous signals and conditions, the ability to
provide rapid adaptive response to changing stimuli, and the ability to preserve cell state via
autoregulatory feedback. Consistent with the underlying biology, and in contrast to transcrip-
tional networks, the vast majority of pARACNe-inferred interactions have a positive Spearman
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Fig 2. Predicted TK-TK network and validation of EGFR and c-MET prediction. (A) pARACNe-inferred densely inter-connected
TK-TK network, with red nodes representing candidate TKs involved in auto-phosphorylation, where the phospho-state of a tyrosine is
correlated with the phospho-state of a different tyrosine on the same TK protein. (B) pARACNe-inferred EGFR and (C) c-MET
substrate overlap with SILAC-based and Database reported substrates, respectively.
https://doi.org/10.1371/journal.pone.0208646.g002
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correlation, with higher counts of TK-mapped phosphopeptides corresponding to higher
counts of candidate substrate-mapped ones. This is consistent with the fact that TKs only
auto-phosphorylate or phosphorylate their substrates, thus inducing positive phospho-state
correlation. Only a negligible number of inferred interactions (0.5%) were associated with a
negative Spearman correlation (N = 11, p� 0.05). These may represent either indirect interac-
tions where the TK activates a substrate-specific phosphatase or direct interactions where
phosphorylation of one phosphosite may prevent phosphorylation of another site on the same
protein.
LUAD network accuracy and sensitivity analysis
To estimate the accuracy of the inferred TK-signaling network, we investigated the sub-
strates of two TK-proteins, EGFR and c-MET, representing high-affinity binding targets
of existing FDA-approved TK inhibitors for LUAD. Specifically, we compared their
pARACNe-inferred substrates to those reported in the phosphoDB database [35] and
those supported by experimental evidence, based on previously published SILAC assays,
following cell line treatment with associated, selective TK inhibitors. pARACNe inferred
123 EGFR substrates (Fig 2B). Of these, 5 (blue and cyan) were included as high-confi-
dence EGFR substrates in phosphoDB, out of 13 in total (38%), including the established
EGFR auto-phosphorylation site. Moreover, 50 additional proteins (45%, green) showed
significant decrease (at least 2 fold) in the abundance of their phosphorylated isoforms in
SILAC assays [34], following treatment of H3255 cells with the EGFR inhibitor Gefitinib.
Similarly, pARACNe predicted 179 c-MET substrates (Fig 2C). Notably, both of the estab-
lished substrates reported in PhosphoDB were identified by pARACNE (100%, blue).
Moreover, 126 additional proteins (71.5%, green) showed significant decrease in the
abundance of their phosphorylated isoforms in SILAC assays [34], following treatment
of MKN45 cells with the first-generation c-MET-specific inhibitor Su11274. We used
MKN45 to assess overall prediction accuracy (Fig 2C), even though it represents a gastric
cancer cell line, because signaling pathways such as EGFR-MAPK pathways proteins
signaling are highly conserved across tissue and species [36]. Also, kinase interaction
network structure and topology is conserved across spices [37]. Indeed, while lineage-spe-
cific chromatin state represents a major determinant of transcriptional regulation, it only
affects signal transduction in terms of overall protein availability.
Taken together, these data suggest that pARACNe can identify a much larger subset of can-
didate substrates, while both identifying a significant proportion of established substrates (46%
on average, based on phosphoDB) and maintaining high accuracy (~60% on average, by
SILAC assays). This also suggest that, similar to transcription factor targets reported in the lit-
erature, TK substrates are still poorly characterized in existing repositories, even for highly rel-
evant and exceedingly well-studied kinases such as EGFR and c-MET. As a result, pARACNe
could provide significant novel hypotheses for TK!S interactions that can be validated as
required. We should also note that the reported accuracy for pARACNe is estimated using
SILAC data on a single cell line. SILAC assays, like all the other phosphorproteomics assays,
have significant false negatives and it would be reasonable to expect that, once tested in addi-
tional cell lines, the accuracy of pARACNe could further increase. As a further performance
benchmark, we used the same SILAC benchmark to test predictions by NetworkIN, a reverse
engineering method based on protein sequence motif analysis and protein association net-
works [17]. The analysis found almost no consensus with SILAC assays, with only one out of
33 NetworkIN-predicted EGFR substrate identified as significantly dephosphorylated follow-
ing treatment with TK-specific inhibitors.
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Systematic, network-based inference of pharmacological dependencies
Once an accurate model of signal transduction in LUAD cells was established by pARACNe
analysis, we interrogated the corresponding TK!S network using phosphoproteomic signa-
tures from 46 LUAD cell lines to identify key dependencies for experimental validation. For
this purpose, we extended the VIPER algorithm (Virtual Proteomics by Enriched Regulon
analysis)[23], which was originally developed to identify the Master Regulator (MR, a protein
that regulate a collection of network substrates [28]) proteins that mechanistically regulate the
transcriptional state of a tumor by assessing the enrichment of their transcriptional targets in
differentially expressed genes in the tumor signature. VIPER and its predecessor MARINa
(Master Regulator Inference algorithm) [38] have been instrumental in inferring MR proteins
representing key functional determinants of tumor-related phenotypes in many cancer types,
from glioblastoma [28, 29, 39], neuroblastoma [38], lymphoma [40, 41], and leukemia [42] to
prostate [43–45] and breast adenocarcinoma [46–48], among others. We thus reasoned that
VIPER could be modified to identify master regulator TKs, most likely to mechanistically reg-
ulate the differential phosphorylation pattern observed in a specific tumor sample (Fig 3A). A
specific additional value of the algorithm is that, as previously shown [28, 38, 43], it could not
only identify MR TK proteins, representing individual, pharmacologically accessible depen-
dencies of the tumor, but also TKs representing potential synergistic MR-pair as candidate
dependencies for combination therapy.
VIPER can be easily modified to analyze phosphoproteomic signatures (pVIPER). Specifi-
cally, rather than assessing the enrichment of a protein’s transcriptional targets (regulon) in
differentially expressed genes, pVIPER is designed to measure the enrichment of a TK’s sub-
strates (signalon) in differentially phosphorylated proteins. Since inferred TK-substrate inter-
actions are virtually all positive, this further increases the accuracy of the algorithm by
supporting use of a single-tail enrichment analysis as opposed to the three-tail analysis of the
original implementation. We first performed pVIPER analysis at the individual phosphopep-
tide level, rather than by averaging phosphopeptide state on a whole protein level. We then
combined the result of the analysis across all phosphopeptides mapping to the same protein.
Consistent with VIPER’s experimentally validated ability to identify synergistic master regula-
tors proteins by transcriptional network analysis, pVIPER inferred several candidate synergis-
tic TK interactions based on the statistical significance of the signature-enrichment of
substrates shared by both TKs compared to that of substrates uniquely mapped to either one
or the other TK (see Method section). Systematic VIPER analysis of phosphoproteomic pro-
files from 46 LUAD cell lines generated between 2 and 13 master regulator TKs or synergistic
TK-pairs, as candidate pharmacologically actionable dependencies, for each cell line, thus gen-
erating a plausible number of hypothesis for each cell line (Fig 3B and Fig 3C).
pVIPER identifies LUAD-specific dependencies
pVIPER analysis inferred several TK proteins as highly conserved individual dependencies
across multiple cell lines, including the Ephrin type-A receptor 2 (EPHA2), epidermal growth
factor receptor (EGFR), c-Met proto-oncogene (MET), and HER2 receptor tyrosine kinase 2
(ERBB2), suggesting a critical role of these proteins in the maintenance of LUAD cell line state.
This is also in agreement with the functional role of these genes and the use of inhibitors of
these kinases across a large panel of patients in multiple cancer types [49–53].
In contrast to these established LUAD cell line dependencies, we also identified several TKs
as dependencies of specific cell lines. This can either be the result of associated genetic or epi-
genetic alterations in these cell lines or the result of field effects, where multiple genetic alter-
ations or alterations in upstream pathway contribute to the cell line dependency on a specific
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Fig 3. Inference of master regulator and combination. (A). Schema of Master Regulator analysis in lung cancer using pVIPER. (B)
shows prioritized Master Regulators and (MR) (C) shows prioritized Master Regulator Pairs as significantly activated (red circle) or de-
activated (blue) molecules in different lung cancer cell lines (by column). In panel (B) and (C), pVIPER infers, for each MR / MR pairs in
each cell line, the enrichment of the MR’s target peptides’ in the differentially phosphorylated peptides compared to the average of all
normal samples. The size and color represent the scale of enrichment. Red color represents an enrichment of substrates hyper-
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TK activity. For instance, we identified ALK (Anaplastic Lymphoma Receptor Tyrosine
Kinase) to be addiction point only in H2228 cell line. ALK is a conserved trans-membrane
receptor tyrosine kinase (RTK) protein in the insulin-receptor super family. Chromo-
somal alterations involving ALK translocations and fusion events have been identified in
several cancer types including LUAD [54, 55], diffuse large B-cell lymphomas [56], neuro-
blastoma [57], and inflammatory myofibroblastic tumors [58], among others. Addition-
ally, ALK fusion events with other genes, including EML4 (Echinoderm Microtubule-
associated protein Like 4) in LUAD lead to aberrant protein activity eliciting “oncogene
addiction” [55]. Presence of EML4-ALK fusion transcripts, in ~3–7% of LUAD patients
[59–61], is a strong predictor of response to ALK inhibitors, such as Crizotinib, among
others [62, 63]. Interestingly, among all available LUAD cell lines for which a phospho-
proteomic profile was available, H2228 was the only one with an established EML4-ALK
fusion event and with established sensitivity to ALK inhibitor [64, 65]. This further
reflects the specificity of our analysis as this was the only cell line predicted to depend on
ALK activity. Interestingly, we identified 4 additional H2228 dependencies, namely
EGFR, Epha2, c-MET, and PTK2. H2228 sensitivity to EGFR inhibitors, in combination
with ALK inhibitors, was already established [65].
EGFR and c-MET are predicted dependencies in multiple LUAD cell lines
As discussed, pVIPER analysis revealed several TK-pairs as candidate synergistic dependencies
across several cell lines, such as Epha2/c-MET, EGFR/PTK2, EGFR/Epha2, Epha2/c-MET,
and EGFR/c-MET. Previous study shows that Epha2 blockade could overcome acquired resis-
tance to EGFR kinase inhibitors in Lung Cancer [66]. Among other predicted pairs, the
EGFR/c-MET pair emerged as the most conserved synergistic TK-pair across the available cell
lines. In addition, EGFR and c-MET were also identified as candidate TK MRs in several of
these cell lines, suggesting either a complementary or synergistic role for these proteins and a
potential therapeutic opportunity for combination therapy in LUAD [67, 68].
To validate pVIPER-predicted, cell line specific EGFR/c-MET synthetic lethality, we selected a
panel of 14 cell lines, 11 of which were predicted to be synergistically dependent on EGFR/c-MET
(H226, H2122, H1666, H2172, Cal-12T, H2023, H1568, Calu-3, H1650, HCC78, and A549), as
well as 3 negative controls with no predicted synergistic or individual dependencies on the two
TKs (H2170, H460, and H520). To measure sensitivity to these agents, we used two different and
complementary assays, including: (a) colony formation assay to assess long term sensitivity (Fig
4A, S3 Table and Methods) and (b) 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bro-
mide (MTT) assay for short term sensitivity analysis (Fig 5A, S4 Table and Methods). For colony
formation assays, cells were treated with either an EGFR inhibitor (Erlotinib, 1uM) or a c-MET/
ALK inhibitor (Crizotinib, 0.1uM), either individually or in combination (see Methods). To evalu-
ate synergistic dependency on EGFR/c-MET we used Excess Over Bliss [69], which measures the
difference between the observed effect on colony formation and the effect expected from a purely
additive model. For MTT assay, first, cells were treated with EGFR inhibitor (Erlotinib) or MET
inhibitor (Crizotinib) individually at various concentrations to identify IC50 (concentration result-
ing in 50% cell death). Next, cells were treated with 1 uM of Erlotinib and varying concentrations
of Crizotinib to identify combinations resulting in IC50 and used the combination index (CI) sta-
tistic [70] to measure interaction between the two drugs.
phosphorylation by a Master Regulator or Master Regulator Pairs. Blue color represents that of hypo-phosphorylation. A white small
circle refers to no significant enrichment; red (blue) large circle represents substrates of a kinase to be significantly hyper (hypo)-
phosphorylated in the corresponding cell line when compared with the average from all normal samples.
https://doi.org/10.1371/journal.pone.0208646.g003
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Fig 4. Experimental validation of EGFR and c-MET combination by colony formation assay. (A) Colony formation assay schema
shows the image of long-term EGFR and c-MET double inhibition effects in HCC78 cell line with different treatments. (B) shows long-
term colony formation data for 14 cell lines with different EGFR, BRAF and KRAS genomic mutation status.
https://doi.org/10.1371/journal.pone.0208646.g004
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Fig 5. MTT Assay validation of EGFR and c-MET combination. (A). MTT assay experimental schema. (B) MTT assay of HCC78 cell
line shows synergistic effects of Crizotinib and Erlotinib treatment. (C) shows short-term effects of EGFR and c-MET inhibitors’
combination index in 11 cell lines include 2 control cell lines (red).
https://doi.org/10.1371/journal.pone.0208646.g005
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Across all 11 cell lines tested in colony formation assay, 8 showed significant sensitivity
(Based on half maximal inhibitory concentration, IC50, which represents the concentration of
a drug that is required for 50% inhibition) to either individual inhibitors (H226E,C, H2122E,
H1666E,C, Cal-12TE, Calu-3E,C, H1650E) or synergistic sensitivity to the combination
(HCC78E+C and H2023 E+C) (Fig 4A). The sensitivity of a drug was is defined using IC50
according to [71]. Surprisingly, all of these cell lines were EGFRWT, ALKWT, and c-METWT,
except for H1650, which was EGFRMut. Thus, based on standard of care criteria, 7 out of 8 cell
lines would not have been considered as sensitive to either EGFR or ALK/c-MET inhibitors.
Several cell lines presented striking sensitivity to either one (H2122E, Cal-12TE, H1650E) or
both inhibitors (H226E,C, H1666E,C, Calu-3E,C) in isolation, thus making the assessment of
synergistic drug sensitivity difficult. In addition, three EGFRWT cell lines harboring BRAF
(Cal-12T and H1666) or KRAS (H2122) mutations were also highly sensitive to Erlotinib as a
single agent, as predicted by pVIPER, despite the fact that KRAS pathway mutations are mutu-
ally exclusive with EGFR mutations and predictive of Erlotinib resistance (Fig 4B). Finally,
none of these cell lines was predicted to be sensitive to ALK inhibitors, suggesting that Crizoti-
nib sensitivity is mediated by c-MET specific dependencies. Of the negative controls, only one
(H2170) showed high sensitivity to Erlotinib. Taken together, 8/11 cell lines (73%) predicted
as sensitive to the inhibitors were validated long term colony formation assays, while only 1/3
negative controls showed sensitivity to these agents (33%).
To evaluate the short-term interaction between EGFR and c-MET, we performed MTT
assay across 11 cell lines (HCC78, H2023, H1650, Calu-3, H2172, H2122, H1568, A549,
H1666, H520 and H2170) including 2 negative control cell lines (H520 and H2170). Similar to
colony formation assay, we found synergistic sensitivity to EGFR and c-MET inhibitors in 6/9
cell lines (67%), with 5 cell lines showing strong synergy (CI� 0.8) (Fig 5B and 5C) and 1 bor-
derline synergy (CI = 0.82), showing the consistency between two assays. However, for two
cell lines, H1666 and H2170 (a negative control), results were inconsistent between long term
colony formation and MTT assays. For both H1666 and H2170 cell lines, colony formation
and MTT assay to showed sensitivity to Erlotinib alone, where colony formation assay has
complete abrogation of colonies at 1 μM of Erlotinib, and later had IC50 = 1.25 μM and 3.7 μM
for H1666 and H2170 respectively. However, in combination therapy, MTT assay showed
antagonism (CI>1), despite the fact that colony formation assay still showed complete abro-
gation which could be either the difference in the nature of the two assays or associated to the
accumulation of new mutations in these cell lines. However, this is just hypotheses and needs
to be verified by further experiments such as sequencing of these cell lines pre-and post-
treatment.
Phosphosite-specific phosphorylation predicts EGFR/c-MET inhibitor
synergy
In previous section, we assessed the pVIPER predictions after consolidating the result at pro-
tein level. Following the results from MTT and colony formation assays, we reanalyzed the
pVIPER predictions at the phosphopeptide level. Interestingly, this revealed that whenever
synergistic EGFR/c-MET dependencies were predicted from phosphosite EGFR1197 and phos-
phosites other than c-MET1003 (H1666, Cal-12T, H1650), cell lines responded to Erlotinib in
isolation, while when predictions were based on phosphosites EGFR1197 and c-MET1003
(HCC78, H2023, and Calu-3), cells exhibited bona fide synergistic sensitivity to the two inhibi-
tors, with the only possible exception of Calu-3, which showed synergistic sensitivity in MTT
assays and additive sensitivity to both inhibitors in colony formation assays. Conversely, when
predictions were not based on either phosphotyrosine, cells exhibited no sensitivity to the
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individual inhibitors or the combination (H2172, H226, A549, H460, H520, H1568). Thus,
predictions based on these two phosphosites produced no false positives (6 out of 6 predicted
and validated as non-sensitive) and only 2 false negatives (H2170 and H2122), resulting in an
error rate of only 2 out of 14 cell lines (14%, p = 0.0093 using fisher exact test).
This finding is in agreement with the previously reported finding that the level of tyrosine-
1197 phosphorylation on EGFR is predictive of sensitivity [72]. Intriguingly, when sensitivity
was predicted using phosphosites other than EGFR1197 and c-MET1003, cell lines did not
respond to the inhibitors, either individually or in combination. For these two peptides, we
found their common substrates to be hyper phosphorylated in the sensitive cell lines (Fig 6A)
compared to the specific substrates of each of them, whereas cell line responding only to EGFR
inhibitors showed more hyper phosphorylation of EGFR only substrates (Fig 6B). Cell lines
resistant to both EGFR and c-MET inhibitors either showed no change in the phosphorylation
status or hypo-phosphorylation compared to the normal samples (Fig 6C). Hence, either the
common substrates of EGFR and c-MET, or the phosphorylation status of EGFR1197 and c-
MET1003 could potentially be used as biomarkers for predicting therapy with the dual inhibi-
tors. However, this conclusion is based on a very limited number of observations and lacks the
statistical power. This finding needs a re-evaluation/validation using larger cohort of samples
to establish an appropriate biomarker for combination therapy.
Systematic inference of patient-specific dependencies
Similar to cell lines, when applied on patient data [34], pVIPER identified the tyrosine phos-
phorylation level of EGFR to be one of the most predictive kinases (Fig 6). We inferred EGFR
dependency in 12 patients. Of these, 5 harbored EGFR mutations, while the remaining 7
patients had not been tested for this mutation, showing a high consistency between our predic-
tions and the genetic predisposition for sensitivity to EGFR inhibitors. In the entire cohort,
there were only 3 patients with EGFR mutations that were not identified as EGFR dependent
by pVIPER, resulting in an overall sensitivity of 62.5% (5/8). However, it is well known from
literature that >50% of patients harboring EGFR mutations do not respond to Erlotinib [73]
suggesting that these may not be false negatives but rather patients with low activation of
downstream EGFR pathways, despite their EGFRMut state. Similarly, our analysis identified
candidate ALK dependencies in 4 patients. Of these one had an established TFG-ALK fusion,
whereas the others had not been tested for ALK fusion events.
Across all patient samples, we observed Discoidin Domain Receptor-1 (DDR1) to be the
most frequent addiction point, which was not predicted for any of the 46 cell lines. One reason
for the difference is that DDR1 is collagen dependent and there may be differences in the 3D
structure of the tumor and the cell lines growing on the plate. An independent study [74] in a
cohort of 83 lung cancer specimens found that silencing of DDR1 in these samples leads to the
hampering of cell survival, reduced invasiveness in collagen matrices, increased apoptosis in
basal condition and decreased metastatic activity in model of tumor metastasis to bone, signi-
fying it as a potential novel therapeutic target.
Discussion
In this paper, we developed pARACNe to infer Tyrosine Kinase (TK) signaling network using
published global phosphoproteomic data from lung cancer. The network prediction was vali-
dated using SILAC experiments, with high accuracy. Interrogation of the predicted TK-sub-
strate network generated biologically meaningful hypotheses, followed by experimental
validations illustrating the effectiveness of predicted kinase inhibitor combination, EGFR and
c-MET combination inhibitors, in treating lung cancer cell lines. Furthermore, Master
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Fig 6. Master regulating peptides in primary lung cancer samples. EGFR and c-MET co-regulate in three scenarios (A) when their
common substrates are hyperphosphorylated, the patient responds to combination treatment well; (B) when most EGFR substrates are
hyper-phosphorylated, the patient responds to EGFR inhibitor; (C) when substrates of both EGFR and c-MET are mostly
hypophosphorylated, the patient does not respond. (D) shows the Master Regulator and Master Regulator Pairs regulating hyper/hypo-
phosphorylation of their network substrates in each primary samples. In panel (A-C), Red node represent hyper-phosphorylated, yellow
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Regulator Analysis using patient proteomics data provides implications for using targeted
agent combinations to treat patients based on their proteomic profile data.
The new method, pARACNe, addresses critical issues that prevented the direct application
of the original ARACNe algorithm on phosphoproteomic profile data. Briefly, the new algo-
rithm addresses critical computational challenges presented by LC-MS/MS and spectral count-
ing data, while incorporating enzymatic signaling characteristics into the algorithm design. In
particular, pARACNe is designed to handle three critical issues resulting from the use of
LC-MS/MS assays, including the highly sparse nature of phosphopeptide abundance data, the
large amount of noise and missing data, and the degenerate peptides-to-protein mapping. The
algorithm could be applied to proteomics measurements after preprocessing of the original
data. For example, where there are datasets from different programs, they could be first trans-
formed into rank based on total peptides identified. When mapping across datasets, one can
fill in missing data using 0 –this type of data could be properly handled by the Iterative Quan-
tile Discretization process in pARACNe. Future improvement of pARACNe includes design of
a new schema to directly compute Mutual Information from continuous MS/MS data with
many missing value produced by multiplexing platforms.
Notably, pARACNe is significant and powerful as of its global scale and context-specificity
in discovering global signaling cascading relationships, which were missing by previous meth-
ods. For example, methods proposed by Linding et al. [17] combine motif-based phospho-site
predictions with information of physical association, co-occurrence, and co-expression to
identify substrates with high specificity and accuracy, but with low coverage and lack of con-
textual specificity. Bender et al [18] used reverse phase protein assay data after various stimula-
tions to cells and inferred signaling network using hidden Markov models and genetic
algorithms. Even though the resulting networks are context specific, they lack genomic-scale
coverage. There have been methods which used existing large-scale protein networks and
prune them using transcriptomic information to identify signaling pathways [75–77]. In addi-
tion, attempts have been made to reconstruct signaling network using gene expression data
[78, 79]. However, as signaling complexity lies mostly in upper level of cellular processes, infer-
ring the cascades from downstream gene expression fails to capture all the dynamics. Also,
PrePPI proposed by Zhang et al. [80] used protein structure-based methods to infer global pro-
tein-protein interaction, but this approach fails to address phosphorylation context specificity.
Innovative uses of multiplex and microarray-based approaches, where multiple antibodies can
be used to probe an ensemble of phosphoproteins, are finally becoming sufficiently mature to
allow characterization of small pathways. Yet, these methods are still far from providing an
unbiased, global view of tyrosine signal-transduction processes and continue to be completely
dependent on antibody specificity and availability. Similarly, assays that are generally used to
monitor phosphorylation pathways, such as Stable Isotope Labeling with Amino acids in Cell
culture (SILAC), provide a simple and straightforward approach to detect differential protein
abundance. Coupled with phosphorylation enriched assays, it can provide high quality quanti-
fication for post-translation phosphorylation changes in cell lines. However, these methods are
1) laborious and costly; 2) can only be performed to dissect the substrates of a single enzyme at
a time and 3) do not differentiate between direct and indirect targets. Recently developed
TMT/iTRAQ experiments uses multiplexing strategy to investigate multiple treatments or
Kinase knock-out/knock-down experiments [81, 82], thus making the process high-through-
put at reduced the cost, however still cannot provide evidence for direct targets.
node represent hypo-phosphorylated and gray represents un-differentiated phosphorylated proteins compared to average normal
samples.
https://doi.org/10.1371/journal.pone.0208646.g006
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To be noted, as the LC-MS/MS experiments used here was generated based on Tyrosine-kinase
enrichment, which is only about ~2% of whole phosphoproteome. pARACNe is shown only on
TK-substrates network. The current methodology could be extended to whole phosphoproteomic
data based signaling network reconstruction where the data is available. In addition to label free
based LC-MS/MS proteomics data used in this work, label-based approaches, such as ITRAQ or
TMT, could generate higher throughput whole proteomic profiles which might require future
redesign of ARACNe to incorporate both kinases and phosphatases in regulating their down-
stream substrates. It is reasonable to expect that a version of ARACNe developed specifically to
dissect signaling networks should work at least as well as its transcriptional counterpart. Since the
relationship between the mRNA abundance of a gene encoding a transcription factor (TF) and
the activity of the corresponding protein is much looser than that between the abundance of a
phospho-isoform of a kinase and its enzymatic activity.
Even though research has attempted to identify addiction points based on gene expression
data [83], predictions based on phosphoproteomic data appear superior in a way that they can
directly reflect contextual specific signaling activity and are able to be directly targeted by
kinase inhibitors. It is important to note that clinically, only patients with base-pair deletion at
exon 19 (del746_A750) or a point mutation at exon 21 mutation (L858R) in EGFR shows sen-
sitivity to EGFR inhibitor such as Cetuximab or Erlotinib [84]. In the future, whole phospho-
proteomic data and tools could be used in combination with transcriptome-based approaches




The previously published phosphoproteomic data used to reconstruct signaling network was
download from [54]. This dataset, representing the abundance of phospho-tyrosine containing
peptides, was obtained by tandem mass spectrometry analysis of 46 non-small cell lung cancer
(NSCLC) cell lines, 151 NSCLC tumors, and 48 normal lung tissue samples. Immunohis-
tochemistry and a phospho-tyrosine specific antibody were used to screen 96 paraffin-embed-
ded, formalin fixed tissue samples from NSCLC patients as described by Rikova et al.[54].
About 30% of tumors showed high-levels of phospho-tyrosine expression. Immunoblotting of
46 NSCLC cell lines with a phospho-tyrosine specific antibody also showed heterogeneous
reactivity especially in the molecular weight range characteristic of receptor tyrosine kinases.
Since phospho-tyrosine represents less than 1% of the cellular phosphoproteome, as deter-
mined by tandem mass spectrometry (MS/MS), and is difficult to analyze by conventional meth-
ods, immuno-affinity purification was performed with a phospho-tyrosine antibody to enrich for
phospho-tyrosine containing peptides prior to tandem mass spectrometry. All tumors were iden-
tified as NSCLC based on standard pathology. Only those tumors with greater than 50% of cancer
cells were considered for further analysis. NSCLC cell lines were grown overnight in low serum to
reduce background phosphorylation from culture conditions.
Tandem MS profiling identified 3920 tyrosine phosphorylation sites on approximately
2600 different proteins. 85% of these sites appeared to be novel when compared against Phos-
phoSite (http://www.phosphosite.org), a comprehensive resource of known phosphorylation
sites.
pARACNe algorithm
ARACNe is originally designed for gene expression data, where expression of genes is usually
continuous and non-sparse. Quantitative data obtained from label-free LC-MS/MS by data-
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dependent acquisition via spectral counting is discrete and very sparse, with many phospho-
peptides counts not observed for multiple peptides in each sample causing the current version
of ARACNe to be not suitable for this data, which thus required major modifications to handle
discrete data. To handle discrete abundances, we modified the mutual information computa-
tion approach from a kernel density estimation based method to a Naïve based estimation of
mutual information, which is a histogram based technique[85]. Briefly, consider a collection of
N simultaneous measurements of two genes X and Y. Data is partitioned into M discrete bins
ai, and ki denotes the number of measurements that lie within the bin ai. The probabilities p
(ai) are then approximated by the corresponding relative frequencies of occurrence pðaiÞ !
ki
N
and the mutual information I(X,Y) between datasets X and Y is expressed as








Here kij denotes the number of measurements where X lies in ai and Y in aj and N total
number of samples.
Accuracy of mutual information is dependent on correct numbers of bins, M. To find the
optimal number of bins we applied ARACNe on the whole dataset by varying M from 1 to 20
and testing the connections in predicted sub-network against the set of known connections
(gold standard) from databases (phosphoDB) [35].
In case of continuous data, partitioning can be achieved by dividing the range of data into
M equally spaced distance bins. Our data being discrete, equally spaced partitioning was not
possible. So, to overcome this problem, we used an iterative approach of partitioning (Fig 1C).
The basic idea is to divide the number of N data points into M with each bin containing equal
number of data point. If the data point(s) with the same value falls into consecutive bin(s), we
put those data point(s) into current bin and repartition the remaining points into remaining
number of bins. We keep iterating this till we finish either the bins or there are no more data
points to bin. For example, in Fig 1C step (3), we initially partition N points into 4 bins. The
data points with 0 value does not fit into first bin and falls into subsequent bins, so we assign
all data points with 0 value into first bin and repartition the remaining points into 3 bins. We
keep on doing this process till we achieve 4 bins.
To evaluate initial performance and decide number of bins, we computed the network
among all tyrosine kinases and substrates, parsed the sub-network between 49 tyrosine kinases
and 114 substrates which were present in PhosphoSite database and compared the results with
the connections present in database. From our analysis, we found that M = 10 to be an optimal
number (S1 Fig) which gave us precision of 14% and sensitivity of 24%. This precision is an
underestimate of real precision as in the gold standard many interactions are not present.
Master regulator analysis
To discover the master regulator in various cell lines, we interrogated the network
obtained from pARACNe using a novel algorithm, VIPER (Virtual Proteomics by
Enriched Regulon analysis) [23], designed to infer kinases that are key players in a partic-
ular cell line. Protein activity is a good indicator of key kinases in a particular phenotype
but often phosphorylated state of a protein is not sufficient to determine its activity both
due to measurement noise in phosphorylated state as well as LC-MS/MS technique noise.
To overcome this problem, VIPER infers kinase activity from the global kinase substrate
relationship and its biological relevance by overlapping this information in a particular
phenotype-specific program.
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VIPER requires a network model and signature of the phenotype transition (i.e., all genes
ranked by their differential phosphorylation in two phenotypes). Here, the signature, Skin, was
obtained by t-test analysis by comparing each cell line against all normal samples. First, we
associate each kinase with positive and negative activity targets, by computing the correlation
between each kinase and its predicted substrates and selecting only those substrates which had
a significant correlation (p-value� 0.05, Bonferroni corrected). Second, for each kinase we
computed an activity by measuring the enrichment of the Skin signature in predicted substrates
list, separately for both positive and negative correlated, (Skin-enrichment). Enrichment was
computed by Gene Set Enrichment Analysis (GSEA). Since very small percentage of kinases
are found to have negative correlation, we did not use those interactions to evaluate
enrichment.
Cell culture
All cell lines were grown in RPMI-1640 with 5% fetal bovine serum and incubated at 37˚C in a
humidified atmosphere containing 5% CO2. Cell lines were fingerprinted using the Perplex 1.2
system (Promega, Madison, WI). Fingerprints were compared to those generated at ATCC
and/or our internal database.
MTT assays
Short term MTT assays (CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega,
Madison WI) were performed as previously described in [86]. Specifically, each drug concen-
tration is octuplicated and the mean with standard deviation of all replicates were used to gen-
erate a curve to allow calculation of the drug IC50 (Inhibitory Concentration of 50%) value.
The assays were repeated at least 3 times and the IC50s are the average of all replicates.
Colony-formation assays
Long term colony formation assays were performed in triplicate in 6-well plates. Cells were
added to media containing drug and incubated for 1–2 weeks such that control wells (no
drug) contained colonies of 50–70 cells each. At such time media was removed and all wells
stained with a solution containing 0.5% crystal violet and 6% glutaraldehyde for 1 hour. The
plates were then rinsed, dried, and colonies were manually counted.
SILAC experiments
EGFR SILAC experiment was performed in H3255 cell line by treating samples with Gefitinib.
c-MET SILAC experiment was performed in c-MET-driven gastric cancer cell line, MKN45,
by using c-MET inhibitor Su11274. For both genes, cells were treated with inhibitors for 3 and
24hr. For control, cells were grown in same conditions but were not treated with the drug. For
our comparison we combined the peptides, which were differentially obtained between treated
and untreated samples, for 3 and 24 hr. More details about the experiment can be obtained
from Guo et al [34].
Gold standard. In PhosphoSite database, there were 282 connections between 49 tyrosine
kinases and 114 substrates.
Supporting information
S1 Fig. Performance of the pARACNe algorithm. To select optimal bin number in pARA-
CNe algorithm, precision and recall curves for various number of bins were computed. Black
curve is when no binning of data is done. When using 10 bins, the algorithm achieved the best
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performance.
(PDF)
S1 Table. pARACNe-inferred TK-peptides/substrate-peptides Interaction Network. A
three-column table. Column one and two are the two interacting peptides. Column one repre-
sents the gene symbol with dollar sign ($) and numbers specify the sites of phosphorylation in
the protein. Column two is the substrate, representing a gene symbol followed by underscore
and a number of phosphorylation sites. Column three is the mutual information between the
two peptides in column one and column two.
(XLSX)
S2 Table. pARACNe-inferred TK-Protein/Substrate Interaction Network. A three column
table includes kinase, mutual information and substrate. Column two is the maximum mutual
information when aggregating the peptide network into protein level network.
(XLSX)
S3 Table. Colony formation assay result. The results for colony formation assay. First column
is the cell line, second column is the treatment used, and third column is the mean number of
colonies (from triplicates) after normalizing to the control group for each cell line.
(XLSX)
S4 Table. MTT assay results. The results for MTT assay. First column is the cell line, second
column is the IC50 for Erlotinib, third Column is the IC50 for Crizotinib, fourth column is the
IC50 of Crizotinib when cell cells were treated with 1 uM of Erlotinib and varying concentra-
tions of Crizotinib and fifth column is the combination index (CI).
(XLSX)
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